Elsevier

The Lancet

Volume 370, Issue 9581, 7–13 July 2007, Pages 12-14
The Lancet

Comment
Clinical update: adverse effects of antiretroviral therapy

https://doi.org/10.1016/S0140-6736(07)61027-7Get rights and content

First page preview

First page preview
Click to open first page preview

References (20)

  • S Grinspoon et al.

    Cardiovascular risk and body-fat abnormalities in HIV-infected adults

    N Engl J Med

    (2005)
  • M Law et al.

    Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week trial in antiretroviral-naive adults

    Antivir Ther

    (2006)
  • R Haubrich et al.

    Metabolic outcomes of ACTG 5142

    14th CROI

    (2007)
  • GJ Moyle et al.

    A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

    AIDS

    (2006)
  • L Slama et al.

    Effect of pioglitazone on HIV-1 related lipoatrophy

    13th CROI

    (2006)
  • J Sutinen et al.

    Uridine supplementation increases subcutaneous fat in patients with HAART-associated lipodystrophy (HAL)

    7th Int Workshop on Adverse Events and Lipodystrophy in HIV

    (2005)
  • PW Mallon et al.

    Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men

    AIDS

    (2006)
  • I Brar et al.

    A comparison of factors associated with prevalent diabetes mellitus among HIV-infected, antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey Cohort

    J Acquir Immune Defic Syndr

    (2007)
  • Class of antiretroviral drugs and the risk of myocardial infarction

    N Engl J Med

    (2007)
  • A Phillips et al.

    Interruption of ART and risk of cardiovascular disease: findings from SMART

    14th CROI

    (2007)
There are more references available in the full text version of this article.

Cited by (66)

  • Lipodystrophy related to HIV—The Brazilian Public Health approach

    2022, Journal of Plastic, Reconstructive and Aesthetic Surgery
    Citation Excerpt :

    Nevertheless, mortality is decreasing, and HIV is becoming a lifelong chronic disease.1 However, despite improved life expectancy and reduced transmission rate, antiretroviral therapy (ART) has a broad spectrum of adverse events and side effects, even with the newer generation of drugs2. Fatigue, nausea, vomiting, diarrhea, and sexual disorders are some non-specific symptoms, and cardiovascular and metabolic complications can occur.2

  • GluT4: A central player in hippocampal memory and brain insulin resistance

    2020, Experimental Neurology
    Citation Excerpt :

    This dual activity offers a potential human model in which to assess the specific impact of GluT4 blockade: patients treated with GluT4-impairing protease inhibitors (PI; indinavir, nelfinavir) vs. those treated with the newer atazanavir, which has a low affinity for GluT4 (Hruz et al., 2008). A common consequence of HIV infection is cognitive impairment including brain pathology, commonly referred to as HIV-associated neurocognitive disorder (HAND) (Clifford and Ances, 2013); the prevalence of HAND has not decreased concomitantly with e.g. decreased viral load (Calmy et al., 2007; Samaras et al., 2007; Carr, 2003; Lindl et al., 2010; Winston et al., 2010; Gannon et al., 2011) and is roughly 30–50% among HIV-infected persons (Heaton et al., 2010). Long-term PI use has been linked to HAND, with symptoms including hippocampal cognitive impairment and Aβ accumulation, resembling central insulin resistance (Green et al., 2005).

  • Current Progress in the Pharmacogenetics of Infectious Disease Therapy

    2017, Genetics and Evolution of Infectious Diseases: Second Edition
View all citing articles on Scopus
View full text